Cannabidiol Usage as an Adjunct Therapy for Crohn's Disease

• Status: Withdrawn
• Trial end date: 2019-07-01
• Target enrollment: 0
• Participant gender: All

Summary

To date, few studies have assessed the efficacy and safety of Cannabinoids, compounds derived from the Cannabis plant, in patients with Crohn's disease. Our study seeks to pilot a randomized, placebo-controlled trial assessing the efficacy and safety of oral cannabinoids as an adjunct therapy in patients with Crohn's disease.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Illinois at Chicago
• Treatments: Cannabidiol

Criteria

Inclusion Criteria:

• Age 18 or older

• English-speaking

• Ileal and/or ileocolonic involvement as demonstrated by most recent endoscopy

• Short CDAI score >150

• Have not received oral or intravenous steroids for >1 month, or with stable dose for >1 month if currently taking

• Stable dose of AZA for >1 month, if currently taking

• Stable dose of anti-TNF inhibitor for >1 month, if currently taking

Exclusion Criteria:

• Pregnant or intend to become pregnant in the next 6 months

• Major abdominal surgery within the past 3 months